Subcutaneous amivantamab and lazertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Results from the phase 2 PALOMA-2 study.
Document Type
Article
Publication Date
6-1-2024
Abstract
[no abstract]
Keywords
283-197-481, 261-492-3532-2373, 613-3267-3650-3634-10059, 613-135-4642-282-153-924, 283-197-481, 613-225-2575-3984, 613-225-325, 613-225-2782, 6, 6, 3, 3, 3, 3, 3, 2, 4310, 3340, 194, 4310, 3340, 3, 3, 1, 1, 1
Divisions
ummc
Funders
Janssen Research Development
Publication Title
Journal of Clinical Oncology
Volume
42
Issue
17_SUP
Publisher
American Society of Clinical Oncology
Publisher Location
TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
COinS